Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 7, Issue 24
December 26 2023
Issue Cover

Table of Contents

EDITORIAL

Celebrating a year of cancer research in Blood Advances
Catherine M. Bollard,Andrew Weyrich
View Articletitled, Celebrating a year of cancer research in <em>Blood Advances</em>

ADVANCES VIEWPOINT

New and emerging therapies for women, girls, and people with the potential to menstruate with VWD
Caterina Casari,Jennifer Leung,Paula D. James
View Articletitled, New and emerging therapies for women, girls, and people with the potential to menstruate with VWD

CLINICAL TRIALS AND OBSERVATIONS

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
Clinical Trials & Observations
Raphael E. Steiner,Steven R. Hwang,Arushi Khurana,Thomas M. Habermann,Narendranath Epperla,Kaitlin Annunzio,Pamela Blair Allen,Katelin Baird,Darina Paulino,Juan Pablo Alderuccio,Izidore S. Lossos,Kevin David,Andrew M. Evens,Karan Pandya,Steven M. Bair,Manali Kamdar,Sheeba Ba Aqeel,Pallawi Torka,Ryan Lynch,Stephen Smith,Lei Feng,Mansoor Noorani,Sairah Ahmed,Ranjit Nair,Francisco Vega,Susan Wu,Penny Fang,Chelsea C. Pinnix,Jillian R. Gunther,Bouthaina S. Dabaja,Hun J. Lee
View Articletitled, Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
Supplemental data
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study
Clinical Trials & Observations
Jessica K. Altman,Tsila Zuckerman,Jamie Koprivnikar,James McCloskey,Vamsi Kota,Michael Keng,Olga Frankfurt,Yasmin Abaza,Dale L. Bixby,Ashkan Emadi,Micah Burch,Bhavana Bhatnagar,Selina M. Luger,Mary-Elizabeth Percival,Ofir Wolach,Michael Craig,Chezi Ganzel,Gail Roboz,Itai Levi,Anna Gourevitch,Liat Flaishon,Shoshi Tessler,Chen Blumberg,Stela Gengrinovitch,Ruth Ben Yakar,Jacob M. Rowe
View Articletitled, Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study
Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study
Clinical Trials & Observations
Saskia K. Klein,Gerwin A. Huls,Otto Visser,Hanneke C. Kluin-Nelemans,Avinash G. Dinmohamed
View Articletitled, Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study
Supplemental data

HEALTH SERVICES AND OUTCOMES

Telehealth serious illness care program for older adults with hematologic malignancies: a single-arm pilot study
Marissa LoCastro,Soroush Mortaz-Hedjri,Ying Wang,Jason H. Mendler,Sally Norton,Rachelle Bernacki,Thomas Carroll,Heidi Klepin,Jane Liesveld,Eric Huselton,Benzi Kluger,Kah Poh Loh
View Articletitled, Telehealth serious illness care program for older adults with hematologic malignancies: a single-arm pilot study
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Ciclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content
Mehrnaz Safaee Talkhoncheh,Aurélie Baudet,Fredrik Ek,Agatheeswaran Subramaniam,Yun-Ruei Kao,Natsumi Miharada,Christine Karlsson,Leal Oburoglu,Anna Rydström,Kristijonas Zemaitis,Abdul Ghani Alattar,Justyna Rak,Kristian Pietras,Roger Olsson,Britta Will,Jonas Larsson
View Articletitled, Ciclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content
Supplemental data
Gata2 noncoding genetic variation as a determinant of hematopoietic stem/progenitor cell mobilization efficiency
Alexandra A. Soukup,Emery H. Bresnick
View Articletitled, <em>Gata2</em> noncoding genetic variation as a determinant of hematopoietic stem/progenitor cell mobilization efficiency
Supplemental data

LYMPHOID NEOPLASIA

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
James N. Gerson,Elizabeth Handorf,Diego Villa,Alina S. Gerrie,Parv Chapani,Shaoying Li,L. Jeffrey Medeiros,Michael Wang,Jonathon B. Cohen,Michael Churnetski,Brian T. Hill,Yazeed Sawalha,Francisco J. Hernandez-Ilizaliturri,Shalin Kothari,Julie M. Vose,Martin Bast,Timothy Fenske,Swapna Narayana Rao Gari,Kami J. Maddocks,David Bond,Veronika Bachanova,Bhaskar Kolla,Julio Chavez,Bijal Shah,Frederick Lansigan,Timothy Burns,Alexandra M. Donovan,Nina Wagner-Johnston,Marcus Messmer,Amitkumar Mehta,Jennifer K. Anderson,Nishitha Reddy,Alexandra E. Kovach,Daniel J. Landsburg,Martha Glenn,David J. Inwards,Kay Ristow,Reem Karmali,Jason B. Kaplan,Paolo F. Caimi,Saurabh Rajguru,Andrew Evens,Andreas Klein,Elvira Umyarova,Bhargavi Pulluri,Jennifer E. Amengual,Jennifer K. Lue,Catherine Diefenbach,Richard I. Fisher,Stefan K. Barta
View Articletitled, Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Supplemental data
Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma
Marie Beck Hairing Enemark,Katharina Wolter,Amanda Jessica Campbell,Maja Dam Andersen,Emma Frasez Sørensen,Trine Engelbrecht Hybel,Charlotte Madsen,Kristina Lystlund Lauridsen,Trine Lindhardt Plesner,Stephen Jacques Hamilton-Dutoit,Bent Honoré,Maja Ludvigsen
View Articletitled, Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma
Supplemental data
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress
Beatriz Gomez Solsona,Heike Horn,Anja Schmitt,Wendan Xu,Philip Bucher,Aylin Heinrich,Sabrina Kalmbach,Nina Kreienkamp,Maik Franke,Florian Wimmers,Laurentz Schuhknecht,Andreas Rosenwald,Mattia Zampieri,German Ott,Georg Lenz,Klaus Schulze-Osthoff,Stephan Hailfinger
View Articletitled, Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress
Supplemental data
Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study
Tomohiro Urata,Yusuke Naoi,Aixiang Jiang,Merrill Boyle,Kazutaka Sunami,Toshi Imai,Yuichiro Nawa,Yasushi Hiramatsu,Kazuhiko Yamamoto,Soichiro Fujii,Isao Yoshida,Tomofumi Yano,Ryota Chijimatsu,Hiroyuki Murakami,Kazuhiro Ikeuchi,Hiroki Kobayashi,Katsuma Tani,Hideki Ujiie,Hirofumi Inoue,Shuta Tomida,Akira Yamamoto,Takumi Kondo,Hideaki Fujiwara,Noboru Asada,Hisakazu Nishimori,Keiko Fujii,Nobuharu Fujii,Ken-ichi Matsuoka,Keisuke Sawada,Shuji Momose,Jun-ichi Tamaru,Asami Nishikori,Yasuharu Sato,Tadashi Yoshino,Yoshinobu Maeda,David W. Scott,Daisuke Ennishi
View Articletitled, Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study
Supplemental data

MYELOID NEOPLASIA

Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome
Adriana Chiaramida,Sandra G. Obwar,Anja E. H. Nordstrom,Maria Ericsson,Aisha Saldanha,Elena V. Ivanova,Gabriel K. Griffin,Dilshad H. Khan,Roger Belizaire
View Articletitled, Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome
Supplemental data
Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial
Janghee Woo,Darlene Lu,Andrew Lewandowski,Huilei Xu,Pablo Serrano,Margaret Healey,Denise P. Yates,Michael T. Beste,Peter Libby,Paul M. Ridker,David P. Steensma
View Articletitled, Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial
Supplemental data
JAK2V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes
Maryam Rafati,Derek W. Brown,Weiyin Zhou,Kristine Jones,Wen Luo,Andrew St. Martin,Youjin Wang,Meilun He,Stephen R. Spellman,Tao Wang,H. Joachim Deeg,Vikas Gupta,Stephanie J. Lee,Yung-Tsi Bolon,Stephen J. Chanock,Mitchell J. Machiela,Wael Saber,Shahinaz M. Gadalla
View Articletitled, <em>JAK2</em><sup><em>V617F</em></sup> mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes
Supplemental data
GPRC5C drives branched-chain amino acid metabolism in leukemogenesis
Yu Wei Zhang,Talia Velasco-Hernandez,Julian Mess,Maria-Eleni Lalioti,Mari Carmen Romero-Mulero,Nadine Obier,Nikolaos Karantzelis,Jasmin Rettkowski,Katharina Schönberger,Noémie Karabacz,Karin Jäcklein,Tatsuya Morishima,Juan Luis Trincado,Paola Romecin,Alba Martinez,Hitoshi Takizawa,Khalid Shoumariyeh,Simon Renders,Robert Zeiser,Heike L. Pahl,François Béliveau,Josée Hébert,Bernhard Lehnertz,Guy Sauvageau,Pablo Menendez,Nina Cabezas-Wallscheid
View Articletitled, GPRC5C drives branched-chain amino acid metabolism in leukemogenesis
Supplemental data
AMPK activation induces immunogenic cell death in AML
Johanna Mondesir,Margherita Ghisi,Laura Poillet,Robert A. Bossong,Oliver Kepp,Guido Kroemer,Jean-Emmanuel Sarry,Jérôme Tamburini,Andrew A. Lane
View Articletitled, AMPK activation induces immunogenic cell death in AML
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Effects of mitapivat-mediated pyruvate kinase activation in sickle cell disease. Mitapivat (AG-348) is an oral allosteric activator of pyruvate kinase (PK), a key enzyme in RBC glycolysis. PK activation decreases 2,3-DPG levels and increases ATP levels in RBCs. This study showed that mitapivat decreased parameters of hemolysis, RBC sickling and vaso-occlusive events and increased hemoglobin (Hb) level and Hb-oxygen affinity.1,3-DPG, 1,3-Disphosphoglycerate; ADP, adenosine diphosphate; P, phosphate; 2,3-DPG, 2,3-diphosphoglycerate; ATP, adenosine triphosphate; 3-PG, 3-Phosphoglycerate; PEP, phosphoenolpyruvate; RBC, red blood cell; Hb, hemoglobin.

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
Clinical Trials & Observations
Myrthe J. van Dijk,Minke A. E. Rab,Brigitte A. van Oirschot,Jennifer Bos,Cleo Derichs,Anita W. Rijneveld,Marjon H. Cnossen,Erfan Nur,Bart J. Biemond,Marije Bartels,Judith J. M. Jans,Wouter W. van Solinge,Roger E. G. Schutgens,Richard van Wijk,Eduard J. van Beers
View Articletitled, One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
Supplemental data

THROMBOSIS AND HEMOSTASIS

Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation
Varun Iyengar,Rushad Patell,Siyang Ren,Sirui Ma,Amanda Pinson,Amelia Barnett,Pavania Elavalakanar,Dhruv S. Kazi,Donna Neuberg,Jeffrey I. Zwicker
View Articletitled, Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation
Supplemental data

TRANSFUSION MEDICINE

Eleven years of alloimmunization in 6496 patients with sickle cell disease in France who received transfusion
Aline Floch,Sophie Viret,Lucile Malard,Sadaf Pakdaman,Alicia Jouard,Anoosha Habibi,Frédéric Galacteros,Anne François,France Pirenne
View Articletitled, Eleven years of alloimmunization in 6496 patients with sickle cell disease in France who received transfusion
Supplemental data

RESEARCH LETTERS

TALLSorts: a T-cell acute lymphoblastic leukemia subtype classifier using RNA-seq expression data
Allen Gu,Breon Schmidt,Andrew Lonsdale,Roshan Jalaldeen,Hansen J. Kosasih,Lauren M. Brown,Teresa Sadras,Paul G. Ekert,Alicia Oshlack
View Articletitled, TALLSorts: a T-cell acute lymphoblastic leukemia subtype classifier using RNA-seq expression data
Supplemental data
Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia
Jerome Tamburini,Sarah Mouche,Clement Larrue,Nicolas Duployez,Audrey Bidet,Auriane Salotti,Pierre Hirsch,Lucie Rigolot,Sylvain Carras,Marie Templé,Fabrizia Favale,Pascale Flandrin-Gresta,Yannick Le Bris,Anne-Sophie Alary,Laurent Mauvieux,Sylvie Tondeur,Eric Delabesse,François Delhommeau,Pierre Sujobert,Olivier Kosmider,on behalf of the French GBMHM
View Articletitled, Very short insertions in the <em>FLT3</em> gene are of therapeutic significance in acute myeloid leukemia
Supplemental data
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
Clinical Trials & Observations
Yuan Jian,Long Chang,Ming-Xia Shi,Ying Sun,Xiao-Xia Chu,Hua Xue,Wen-Rong Huang,Xu-Liang Shen,Jie Ma,Guo-Rong Jia,Ya-Qing Feng,Zhen-Fang Xi,Yan-Hong Zhao,Yan-Ping Ma,Jing Xiao,Guang-Yu Ma,Qing-Ming Wang,Li Bao,Yu-Jun Dong,He-Bing Zhou,Chun-Yan Sun,Guo-Hong Su,Yan Yan,Sai-Yin Qimuge,Li-Ping Su,Jing-Nan Sun,Wei-Wei Tian,Xiu-Li Sun,Hong-Mei ing,Da Gao,Wen-Ming Chen,Jian Li,Wen Gao
View Articletitled, Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
Supplemental data

COMMENTARIES

Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia
Clinical Trials & Observations
Richard M. Stone,Jessica K. Altman,Mikkael A. Sekeres
View Articletitled, Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia
Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke?
Tiziano Barbui,Alessandra Carobbio,Alessandro M. Vannucchi,Valerio De Stefano
View Articletitled, Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke?
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals